(Q48471344)

11 February 2018

title

Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. (English)

1 reference

11 February 2018

1 reference

1 reference

1

1 reference

11 February 2018

Jerold S. Harmatz

3

object named as

J S Harmatz

1 reference

11 February 2018

David J. Greenblatt

5

object named as

D J Greenblatt

1 reference

11 February 2018

Lisa L. von Moltke

4

object named as

L L von Moltke

1 reference

11 February 2018

author name string

D Farkas

2

1 reference

11 February 2018

language of work or name

English

0 references

publication date

18 April 2007

1 reference

11 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

11 February 2018

volume

82

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

54-62

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100211

exact match

0 references

cites work

Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

The use of caffeine as a metabolic probe for human drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

PSYCHOPHARMACOLOGY OF CHLORPHENTERMINE AND D-AMPHETAMINE. A COMPARATIVE STUDY OF THEIR EFFECTS IN NORMAL MALES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

Kinetic and dynamic interaction of brotizolam and ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

The safety and tolerability of zolpidem--an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Zolpidem: a review of its use in the management of insomnia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Minimal rebound insomnia after treatment with 10-mg zolpidem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Behavioral pharmacology of zolpidem relative to benzodiazepines: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

1 reference

7 January 2021

Is coffee a functional food?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine as a psychomotor stimulant: mechanism of action.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Pharmacological rationale for the clinical use of caffeine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine, fatigue, and cognition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine antagonizes several central effects of diazepam.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Benzodiazepines and caffeine: effect on daytime sleepiness, performance, and mood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine and diazepam: separate and combined effects on mood, memory, and psychomotor performance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Food sources and intakes of caffeine in the diets of persons in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Zolpidem 10 mg given at daytime is not antagonized by 300 mg caffeine in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Validity of self-reports of caffeine use

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Interactions of diazepam and caffeine: behavioral and subjective dose effects in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Clinical importance of the interaction of diazepam and cimetidine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Sedative effects and impaired learning and recall after single oral doses of lorazepam.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100211

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100211

1 reference

11 February 2018

Dimensions Publication ID

1051812310

0 references

1 reference

11 February 2018